{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:07:23Z","timestamp":1791068843535,"version":"4.1.0"},"reference-count":40,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:p>\n                    The presence of contamination in the healthcare work environment by one of the types of hazardous drugs, cytostatics, has been found in multiple international studies. Recent studies and guidelines recommend surface monitoring for risk assessment of healthcare professionals\u2019 exposure. The availability of detection techniques is critical to successfully carry out this type of monitoring. The use of new semi-quantitative techniques allows quicker results. The main objective of this study was to determine the existence of hazardous drugs on the working surfaces in different locations of a tertiary hospital using the BD HD Check\n                    <jats:sup>\u00ae<\/jats:sup>\n                    semi-quantitative device. The presence of methotrexate, doxorubicin and cyclophosphamide was analysed at 80, 89 and 82 locations in 10, 13 and 11 clinical units, respectively. A total of 251 samples were analysed. The monitoring results were positive for 13.1% of the analysed samples, with 36.3% of the methotrexate samples, 0% of the doxorubicin samples and 4.9% of the cyclophosphamide samples. Mapping the presence of HD in our hospital has allowed us to evaluate the effectiveness of controls established in the hospital to minimise the exposure of healthcare professionals to hazardous drugs. The speed in obtaining results has enabled immediate corrective actions in cases where contaminated surfaces were detected.\n                  <\/jats:p>","DOI":"10.1177\/10781552211038518","type":"journal-article","created":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T11:25:21Z","timestamp":1632569121000},"page":"1583-1593","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Analysis of chemical contamination by hazardous drugs with BD HD Check\n                    <sup>\u00ae<\/sup>\n                    system in a tertiary hospital"],"prefix":"10.1177","volume":"28","author":[{"given":"Silvia","family":"Valero Garc\u00eda","sequence":"first","affiliation":[{"name":"Instituto de Investigaci\u00f3n Sanitaria La Fe, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2902-6178","authenticated-orcid":false,"given":"Mar\u00eda","family":"Centelles-Oria","sequence":"additional","affiliation":[{"name":"Hospital Universitari i Polit\u00e8cnic La Fe, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1s","family":"Palanques-Pastor","sequence":"additional","affiliation":[{"name":"Hospital Universitari i Polit\u00e8cnic La Fe, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nieves","family":"Vila Cl\u00e9rigues","sequence":"additional","affiliation":[{"name":"Hospital Universitari i Polit\u00e8cnic La Fe, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"L\u00f3pez-Briz","sequence":"additional","affiliation":[{"name":"Hospital Universitari i Polit\u00e8cnic La Fe, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Poveda Andr\u00e9s","sequence":"additional","affiliation":[{"name":"Hospital Universitari i Polit\u00e8cnic La Fe, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,9,25]]},"reference":[{"key":"bibr1-10781552211038518","first-page":"1033","volume":"47","author":"American Society of Hospital Pharmacists","year":"1990","journal-title":"Am J Hosp Pharm"},{"key":"bibr2-10781552211038518","unstructured":"Burroughs G, Connor T, McDiarmid M. NIOSH alert: preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings. DHHS (NIOSH) Publ No. 2004-165."},{"key":"bibr3-10781552211038518","unstructured":"United States Pharmacopeia. USP General Chapter <800> Hazardous Drugs\u2014Handling in Healthcare Settings, USP 2016, http:\/\/www.usp.org\/usp-nf\/notices\/general-Chapter-hazardous-drugs-handling-healthcare-settings."},{"key":"bibr4-10781552211038518","first-page":"455","volume":"50","author":"Valanis BG","year":"1993","journal-title":"Am J Hosp Pharm"},{"key":"bibr5-10781552211038518","doi-asserted-by":"publisher","DOI":"10.1097\/00043764-198812000-00020"},{"key":"bibr6-10781552211038518","doi-asserted-by":"publisher","DOI":"10.1097\/00043764-199908000-00004"},{"key":"bibr7-10781552211038518","doi-asserted-by":"publisher","DOI":"10.1097\/JOM.0b013e3181f73ae6"},{"key":"bibr8-10781552211038518","doi-asserted-by":"publisher","DOI":"10.1097\/JOM.0000000000000249"},{"key":"bibr9-10781552211038518","doi-asserted-by":"publisher","DOI":"10.1191\/1078155205jp155oa"},{"key":"bibr10-10781552211038518","doi-asserted-by":"publisher","DOI":"10.1002\/jat.1735"},{"key":"bibr11-10781552211038518","doi-asserted-by":"publisher","DOI":"10.1007\/BF00385647"},{"key":"bibr12-10781552211038518","unstructured":"General Office of the Basic Portfolio of SNS (Sistema Nacional de Salud [National Health System]) and Pharmacy Services. General Subdepartment of Drug and Medical Device Quality. Good practice guide for drug preparation in hospital pharmacy services, https:\/\/www.sefh.es\/sefhpdfs\/GuiaBPP_JUNIO_2014_VF.pdf (2014, accessed March 2021)."},{"key":"bibr13-10781552211038518","unstructured":"National Institute for Occupational Safety and Health (INSHT). NTP 740: occupational exposure to cytostatics in the healthcare environment, http:\/\/www.insht.es\/InshtWeb\/Contenidos\/Documentacion\/FichasTecnicas\/NTP\/Ficheros\/701a750\/ntp_740.pdf (accessed March 2021)."},{"key":"bibr14-10781552211038518","unstructured":"Carlos III Institute of Health. Good practice guide for workers professionally exposed to cytostatic agents, Madrid, http:\/\/gesdoc.isciii.es\/gesdoccontroller?action=download&id=26\/03\/2014-199edf956b (2014, accessed March 2021)."},{"key":"bibr15-10781552211038518","unstructured":"National Institute for Occupational Safety and Health (INSHT). NTP 1051: occupational exposure to cytostatic compounds: safe systems for preparation, http:\/\/www.insht.es\/InshtWeb\/Contenidos\/Documentacion\/NTP\/NTP\/Ficheros\/1043a1054\/ntp-1051w.pdf (accessed March 2021)."},{"key":"bibr16-10781552211038518","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1078155207082350","volume":"13","author":"ISOPP Standards of Practice","year":"2007","journal-title":"J Oncol Pharm Pract"},{"key":"bibr17-10781552211038518","unstructured":"Oncology Pharmacy Services Quality Standards, (QuapoS 6), https:\/\/esop.li\/wp-content\/uploads\/2019\/12\/Quapos6_spain_HP.pdf (accessed March 2021)."},{"key":"bibr18-10781552211038518","unstructured":"National Institute for Occupational Safety and Health (INSHT). Hazardous drugs. Prevention measures for their preparation and administration, https:\/\/www.insstes\/documents\/94886\/96076\/medicamentos\u00b1peligrosos.pdf\/480686aa-48fc-4b7b-b543-67fe0b32b1cc?t=1527163426908 (accessed March 2021)."},{"key":"bibr19-10781552211038518","unstructured":"NIOSH. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings, 2016. By Connor TH, MacKenzie BA, DeBord DG, et al. Cincinnati, OH: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication Number 2016-161 (Supersedes 2014-138), 2016."},{"key":"bibr20-10781552211038518","doi-asserted-by":"publisher","DOI":"10.1310\/hpj4803-204"},{"key":"bibr21-10781552211038518","doi-asserted-by":"publisher","DOI":"10.1080\/15459624.2017.1316389"},{"key":"bibr22-10781552211038518","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217704990"},{"key":"bibr23-10781552211038518","doi-asserted-by":"publisher","DOI":"10.1177\/1078155216679027"},{"key":"bibr24-10781552211038518","doi-asserted-by":"publisher","DOI":"10.1007\/s10661-014-3969-1"},{"key":"bibr25-10781552211038518","doi-asserted-by":"publisher","DOI":"10.1093\/annweh\/wxx065"},{"key":"bibr26-10781552211038518","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.farma.2011.10.007","volume":"36","author":"\u00c1lvarez AG","year":"2012","journal-title":"Farm Hosp"},{"key":"bibr27-10781552211038518","first-page":"152","volume":"42","author":"Valero-Garc\u00eda S","year":"2018","journal-title":"Farm Hosp"},{"key":"bibr28-10781552211038518","doi-asserted-by":"publisher","DOI":"10.1080\/15459624.2016.1165912"},{"key":"bibr29-10781552211038518","first-page":"107","volume":"1","author":"Connor HT","year":"2016","journal-title":"Pharm Technol Hosp Pharm"},{"key":"bibr30-10781552211038518","unstructured":"Becton, Dickinson and Company. BD HD check system: quick reference guide. Technical Report series: 1000029255602, 2019. Fraklin Lakes, USA: HD."},{"key":"bibr31-10781552211038518","first-page":"629","volume":"49","author":"Hedmer M","year":"2005","journal-title":"Ann Occup Hyg"},{"key":"bibr32-10781552211038518","doi-asserted-by":"publisher","DOI":"10.1177\/1078155218773862"},{"key":"bibr33-10781552211038518","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220907125"},{"key":"bibr34-10781552211038518","doi-asserted-by":"publisher","DOI":"10.1080\/19338244.2013.763757"},{"key":"bibr35-10781552211038518","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/59.10.956"},{"key":"bibr36-10781552211038518","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxz033"},{"key":"bibr37-10781552211038518","doi-asserted-by":"publisher","DOI":"10.1007\/s10661-016-5762-9"},{"key":"bibr38-10781552211038518","first-page":"15","volume":"28","author":"Valero S","year":"2018","journal-title":"Rev OFIL"},{"key":"bibr39-10781552211038518","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2018.03.001"},{"key":"bibr40-10781552211038518","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2018.03.001"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211038518","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552211038518","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211038518","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:25:23Z","timestamp":1777688723000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552211038518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,25]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1177\/10781552211038518"],"URL":"https:\/\/doi.org\/10.1177\/10781552211038518","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,25]]}}}